vs
GENMAB A/S（GMAB）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是Reddit, Inc.的1.3倍（$925.0M vs $725.6M），GENMAB A/S净利率更高（36.3% vs 34.7%，领先1.6%），Reddit, Inc.同比增速更快（69.7% vs 18.7%），GENMAB A/S自由现金流更多（$327.0M vs $263.6M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
GMAB vs RDDT — 直观对比
营收规模更大
GMAB
是对方的1.3倍
$725.6M
营收增速更快
RDDT
高出50.9%
18.7%
净利率更高
GMAB
高出1.6%
34.7%
自由现金流更多
GMAB
多$63.4M
$263.6M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $725.6M |
| 净利润 | $336.0M | $251.6M |
| 毛利率 | 93.8% | 91.9% |
| 营业利润率 | 38.9% | 31.9% |
| 净利率 | 36.3% | 34.7% |
| 营收同比 | 18.7% | 69.7% |
| 净利润同比 | 65.5% | 254.2% |
| 每股收益（稀释后） | $5.42 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABRDDT
| Q4 25 | — | $725.6M | ||
| Q3 25 | — | $584.9M | ||
| Q2 25 | $925.0M | $499.6M | ||
| Q1 25 | — | $392.4M | ||
| Q4 24 | — | $427.7M | ||
| Q3 24 | — | $348.4M | ||
| Q2 24 | $779.0M | $281.2M | ||
| Q1 24 | — | $243.0M |
净利润GMABRDDT
| Q4 25 | — | $251.6M | ||
| Q3 25 | — | $162.7M | ||
| Q2 25 | $336.0M | $89.3M | ||
| Q1 25 | — | $26.2M | ||
| Q4 24 | — | $71.0M | ||
| Q3 24 | — | $29.9M | ||
| Q2 24 | $203.0M | $-10.1M | ||
| Q1 24 | — | $-575.1M |
毛利率GMABRDDT
| Q4 25 | — | 91.9% | ||
| Q3 25 | — | 91.0% | ||
| Q2 25 | 93.8% | 90.8% | ||
| Q1 25 | — | 90.5% | ||
| Q4 24 | — | 92.6% | ||
| Q3 24 | — | 90.1% | ||
| Q2 24 | 96.4% | 89.5% | ||
| Q1 24 | — | 88.6% |
营业利润率GMABRDDT
| Q4 25 | — | 31.9% | ||
| Q3 25 | — | 23.7% | ||
| Q2 25 | 38.9% | 13.6% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | 30.3% | -11.0% | ||
| Q1 24 | — | -242.5% |
净利率GMABRDDT
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | 36.3% | 17.9% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 8.6% | ||
| Q2 24 | 26.1% | -3.6% | ||
| Q1 24 | — | -236.7% |
每股收益（稀释后）GMABRDDT
| Q4 25 | — | $1.24 | ||
| Q3 25 | — | $0.80 | ||
| Q2 25 | $5.42 | $0.45 | ||
| Q1 25 | — | $0.13 | ||
| Q4 24 | — | $4.76 | ||
| Q3 24 | — | $0.16 | ||
| Q2 24 | $3.13 | $-0.06 | ||
| Q1 24 | — | $-8.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $953.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $2.9B |
| 总资产 | $6.5B | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABRDDT
| Q4 25 | — | $953.6M | ||
| Q3 25 | — | $911.7M | ||
| Q2 25 | $1.3B | $734.1M | ||
| Q1 25 | — | $635.7M | ||
| Q4 24 | — | $562.1M | ||
| Q3 24 | — | $515.9M | ||
| Q2 24 | $622.0M | $468.0M | ||
| Q1 24 | — | $968.5M |
股东权益GMABRDDT
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | $5.3B | $2.4B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | $4.4B | $1.9B | ||
| Q1 24 | — | $1.8B |
总资产GMABRDDT
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | $6.5B | $2.6B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | $5.6B | $2.1B | ||
| Q1 24 | — | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $266.8M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $263.6M |
| 自由现金流率自由现金流/营收 | 35.4% | 36.3% |
| 资本支出强度资本支出/营收 | 2.4% | 0.4% |
| 现金转化率经营现金流/净利润 | 1.04× | 1.06× |
| 过去12个月自由现金流最近4个季度 | — | $684.2M |
8季度趋势，按日历期对齐
经营现金流GMABRDDT
| Q4 25 | — | $266.8M | ||
| Q3 25 | — | $185.2M | ||
| Q2 25 | $349.0M | $111.3M | ||
| Q1 25 | — | $127.6M | ||
| Q4 24 | — | $90.0M | ||
| Q3 24 | — | $71.6M | ||
| Q2 24 | $438.0M | $28.4M | ||
| Q1 24 | — | $32.1M |
自由现金流GMABRDDT
| Q4 25 | — | $263.6M | ||
| Q3 25 | — | $183.1M | ||
| Q2 25 | $327.0M | $110.8M | ||
| Q1 25 | — | $126.6M | ||
| Q4 24 | — | $89.2M | ||
| Q3 24 | — | $70.3M | ||
| Q2 24 | $430.0M | $27.2M | ||
| Q1 24 | — | $29.2M |
自由现金流率GMABRDDT
| Q4 25 | — | 36.3% | ||
| Q3 25 | — | 31.3% | ||
| Q2 25 | 35.4% | 22.2% | ||
| Q1 25 | — | 32.3% | ||
| Q4 24 | — | 20.8% | ||
| Q3 24 | — | 20.2% | ||
| Q2 24 | 55.2% | 9.7% | ||
| Q1 24 | — | 12.0% |
资本支出强度GMABRDDT
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | 2.4% | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | 1.0% | 0.4% | ||
| Q1 24 | — | 1.2% |
现金转化率GMABRDDT
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 1.14× | ||
| Q2 25 | 1.04× | 1.25× | ||
| Q1 25 | — | 4.88× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 2.40× | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
